Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus - PubMed (original) (raw)
. 1975 Oct 13;234(2):159-5.
- PMID: 1242153
Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus
J E Gerich et al. JAMA. 1975.
Abstract
Plasma glucose and glucagon responses to standard meals containing carbohydrate, fat, and protein as in normal diets were studied in 12 subjects with insulin-dependent diabetes and 12 normal subjects. Diabetics had two to three times greater glucagon responses than did normal subjects. Fifteen units of insulin injection did not normalize these excessive glucagon responses, although postprandial hyperglycemia was reduced. Infusion of somatostatin at a dosage of 500 mug/hr prevented glucagon responses and diminished postprandial hyperglycemia by 60%. The combination of insulin and somatostatin caused a progressive fall in plasma glucose levels despite meal ingestion. Somatostatin and insulin, administered subcutaneously in the same syringe, also abolished postprandial hyperglycemia. These studies indicate that excessive glucagon secretion participates in the genesis of diabetic postprandial hyperglycemia. Somatostatin, an inhibitor of glucagon secretion, may thus prove useful as an adjunct to insulin in the treatment of diabetes mellitus.
Similar articles
- The inhibitory effect of somatostatin on growth hormone, insulin and glucagon secretion in diabetes mellitus.
Ward FR, Leblanc H, Yen SS. Ward FR, et al. J Clin Endocrinol Metab. 1975 Sep;41(3):527-32. doi: 10.1210/jcem-41-3-527. J Clin Endocrinol Metab. 1975. PMID: 1159060 - Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus.
Dimitriadis G, Tessari P, Gerich J. Dimitriadis G, et al. Metabolism. 1983 Oct;32(10):987-92. doi: 10.1016/0026-0495(83)90140-3. Metabolism. 1983. PMID: 6136893 - Inhibition of glucagon secretion.
Young A. Young A. Adv Pharmacol. 2005;52:151-71. doi: 10.1016/S1054-3589(05)52008-8. Adv Pharmacol. 2005. PMID: 16492545 Review. - Role of glucagon in the pathogenesis of diabetes: the status of the controversy.
Unger RH. Unger RH. Metabolism. 1978 Nov;27(11):1691-709. doi: 10.1016/0026-0495(78)90291-3. Metabolism. 1978. PMID: 360007 Review.
Cited by
- Clinical evaluation of somatostatin as a potential ajunct to insulin in the management of diabetes mellitus.
Gerich JE, Schultz TA, Lewis SB, Karam JH. Gerich JE, et al. Diabetologia. 1977 Sep;13(5):537-44. doi: 10.1007/BF01234510. Diabetologia. 1977. PMID: 908478 - Paracrine signaling in islet function and survival.
Hartig SM, Cox AR. Hartig SM, et al. J Mol Med (Berl). 2020 Apr;98(4):451-467. doi: 10.1007/s00109-020-01887-x. Epub 2020 Feb 17. J Mol Med (Berl). 2020. PMID: 32067063 Free PMC article. Review. - Effect of indomethacin on the metabolic and hormonal response to a standardized breakfast in normal subjects.
Luyckx AS, Guerten D, Scheen A, Delporte JP, Lefebvre PJ, Jaminet F. Luyckx AS, et al. Acta Diabetol Lat. 1981 Jul-Sep;18(3):259-66. doi: 10.1007/BF02047898. Acta Diabetol Lat. 1981. PMID: 7029990 - Newly discovered knowledge pertaining to glucagon and its clinical applications.
Kawamori D, Sasaki S. Kawamori D, et al. J Diabetes Investig. 2023 Jul;14(7):829-837. doi: 10.1111/jdi.14009. Epub 2023 Apr 13. J Diabetes Investig. 2023. PMID: 37052948 Free PMC article. Review. - Effect of glucagon on glucose production during insulin deficiency in the dog.
Cherrington AD, Lacy WW, Chiasson JL. Cherrington AD, et al. J Clin Invest. 1978 Sep;62(3):664-77. doi: 10.1172/JCI109174. J Clin Invest. 1978. PMID: 690190 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources